

Call for Evidence: Economic and Societal Value of Cancer Control Interventions

Cancer results in economic losses of more than €200 billion annually across Europe, driven by healthcare costs, lost productivity, labour market disruption, and premature mortality. Despite this substantial burden, the evidence base quantifying the returns generated by investment in cancer control remains fragmented across interventions, countries, and points along the cancer pathway.

The European Cancer Organisation (ECO) is developing an investment case demonstrating the economic and societal returns of action against cancer, informed by a structured literature review and complemented by this call for evidence. **We are inviting the cancer community to submit evidence on the economic and societal value of cancer control interventions, to strengthen the evidence base underpinning this study.**

Scope

This call seeks published evidence on the economic and societal value of cancer control interventions at the policy and system level. Eligible submissions should assess interventions implemented, piloted, or evaluated at a population, regional, national, or system-wide level rather than individual patient-level clinical care.

Evidence is sought across the full cancer pathway and its horizontal enablers:

- **Prevention** (e.g., risk factor reduction, vaccination programmes)
- **Early detection** (e.g., screening programmes)
- **Diagnosis** (e.g., diagnostic pathways, advanced testing)
- **Treatment and care** (e.g., care delivery models, treatment protocols)
- **Survivorship and quality of life** (e.g., rehabilitation, follow-up care)
- **Research and innovation** (e.g. basic, clinical, implementation research)
- **Infrastructure and data systems** (e.g., registries, health information systems)
- **Workforce** (e.g., training, staffing, retention initiatives)
- **Inequalities and specific population groups** (e.g., interventions improving equitable access)

Submissions should draw on published, peer-reviewed literature or other publicly available, citable sources (e.g., government or institutional reports, official statistics). Assessments may include, but are not limited to, cost-effectiveness analyses, cost-benefit analyses, budget impact assessments, return-on-investment analyses, and evaluations of productivity or health system efficiency gains. Submitted evidence should pertain to geographical Europe.



Who can contribute

We welcome submissions from relevant individuals and organisations within and beyond the ECO community, including from medical societies, patient organisations, academic institutions, health systems managers, policy-makers and others.

What to submit

For each example, please provide:

- Name and description of the intervention
- Country/region and level of implementation/evaluation (national, regional, local)
- Type of economic assessment conducted
- Key findings (e.g., cost data, ROI, QALYs, savings)
- Source/citation, or contact details if unpublished

How to submit

Submissions should be made via the online submission form, which can be accessed [here](#)

Contributors wishing to submit multiple examples are kindly requested to complete a separate form for each submission. The submission deadline is **31 August 2026**.

For any questions regarding this call for evidence, please contact sana.seddiki@europeancancer.org